Sophie M. Ernst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sophie M. Ernst has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Marie Clasina Dingemans
Department of Respiratory Medicine, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands
9 shared publications - Hendrikus Jan Dubbink
Department of Pathology, Brain Tumor Center, Erasmus MC Cancer Institute, University Medical Center Rotterdam, the Netherlands
4 shared publications Jan H. von der Thüsen
Univ Med Ctr, Erasmus MC Canc Inst, Dept Pathol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
4 shared publicationsMarthe S. Paats
Department of Respiratory Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands
4 shared publications- Joachim G. J. V. Aerts
Department of Respiratory Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands
3 shared publications - Adrianus Johannes de Langen
Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- p. 1-7
The Predictive Value of Gastrin for the Absorption of Erlotinib in Patients with Non-Small Cell Lung Cancer
Background and Objective Gastrin regulates gastric acid secretion and increases when gastric acidity is reduced. Erlotinib, a small-molecule inhibitor used to treat patients with advanced non-small cell lung cancer (NSCLC), has a pH-dependent absorption. We therefore investigated whether elevated gastrin levels, for example, due to proton pump inhibitor (PPI) use or achlorhydria, are associated with reduced erlotinib absorption. Methods Data of patients treated with erlotinib for NSCLC that were included in two previously conducted pharmacokinetic studies were used for this pharmacological proof-of-principle analysis. In these studies, patients were randomized to PPI use or not. Gastrin levels were quantified in samples drawn just before intake of erlotinib and used to study correlations with erlotinib concentrations. The pharmacokinetic endpoints area under the curve (AUC), trough concentration, and maximum concentration (Cmax) were correlated to gastrin concentrations and compared in patients with and without hypergastrinemia (gastrin ≥ 150 pg/mL). Results A total of 52 patients on erlotinib were included. Gastrin showed a significant inverse correlation with erlotinib AUC0–12h (r = −0.277; p = 0.047) and Cmax (r = −0.423; p = 0.002). In 11 patients with hypergastrinemia (gastrin ≥ 150 pg/mL), median erlotinib Cmax was > 30% lower (1890 ng/mL vs 1200 ng/mL; p = 0.024). The median AUC0–12h and AUC0–24h of erlotinib showed a non-significant trend towards lower AUCs of, respectively, 29% (p = 0.087) and 23% (p = 0.074), in patients with hypergastrinemia. Conclusions Gastrin concentrations could potentially serve as a marker for erlotinib absorption, helping identify patients at risk for low erlotinib exposure.
- 23 October 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- p. 1-7
Open AccessThe Predictive Value of Gastrin for the Absorption of Erlotinib in Patients with Non-Small Cell Lung Cancer
Background and Objective Gastrin regulates gastric acid secretion and increases when gastric acidity is reduced. Erlotinib, a small-molecule inhibitor used to treat patients with advanced non-small cell lung cancer (NSCLC), has a pH-dependent absorption. We therefore investigated whether elevated gastrin levels, for example, due to proton pump inhibitor (PPI) use or achlorhydria, are associated with reduced erlotinib absorption. Methods Data of patients treated with erlotinib for NSCLC that were included in two previously conducted pharmacokinetic studies were used for this pharmacological proof-of-principle analysis. In these studies, patients were randomized to PPI use or not. Gastrin levels were quantified in samples drawn just before intake of erlotinib and used to study correlations with erlotinib concentrations. The pharmacokinetic endpoints area under the curve (AUC), trough concentration, and maximum concentration (Cmax) were correlated to gastrin concentrations and compared in patients with and without hypergastrinemia (gastrin ≥ 150 pg/mL). Results A total of 52 patients on erlotinib were included. Gastrin showed a significant inverse correlation with erlotinib AUC0–12h (r = −0.277; p = 0.047) and Cmax (r = −0.423; p = 0.002). In 11 patients with hypergastrinemia (gastrin ≥ 150 pg/mL), median erlotinib Cmax was > 30% lower (1890 ng/mL vs 1200 ng/mL; p = 0.024). The median AUC0–12h and AUC0–24h of erlotinib showed a non-significant trend towards lower AUCs of, respectively, 29% (p = 0.087) and 23% (p = 0.074), in patients with hypergastrinemia. Conclusions Gastrin concentrations could potentially serve as a marker for erlotinib absorption, helping identify patients at risk for low erlotinib exposure.
- 29 September 2025
- Published by Elsevier in Lung Cancer
- Vol. 209, 108783
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study
- 29 September 2025
- Published by Elsevier in Lung Cancer
- Vol. 209, 108783
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study
- 14 March 2025
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 22 (5) , 371-378
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials
Advances in targeted therapies for patients with non-small-cell lung cancer have substantially improved the outcomes of those with actionable alterations in certain oncogenic driver genes. However, acquired resistance to these targeted therapies remains a major challenge. Understanding the mechanisms underlying acquired resistance will be crucial for the development of strategies that might either overcome this effect or delay the onset. Circulating tumour DNA, owing to the need for only minimally invasive sampling and a potential role as both a prognostic and predictive biomarker, is increasingly being used in both research and clinical practice. Several studies have explored the landscape of acquired resistance to targeted therapies using this approach. However, the methodologies of the published studies vary widely, and several major challenges remain in addressing the practical difficulties associated with these methods. These challenges currently limit the depth of research insight provided by the available data. In this Perspective, we review clinical reports describing the use of circulating tumour DNA to detect mechanisms of acquired resistance to targeted therapies, predominantly in patients with advanced-stage non-small-cell lung cancer, and highlight key unresolved questions with the aim of moving towards more-informative research studies.
- 14 March 2025
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 22 (5) , 371-378
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials
Advances in targeted therapies for patients with non-small-cell lung cancer have substantially improved the outcomes of those with actionable alterations in certain oncogenic driver genes. However, acquired resistance to these targeted therapies remains a major challenge. Understanding the mechanisms underlying acquired resistance will be crucial for the development of strategies that might either overcome this effect or delay the onset. Circulating tumour DNA, owing to the need for only minimally invasive sampling and a potential role as both a prognostic and predictive biomarker, is increasingly being used in both research and clinical practice. Several studies have explored the landscape of acquired resistance to targeted therapies using this approach. However, the methodologies of the published studies vary widely, and several major challenges remain in addressing the practical difficulties associated with these methods. These challenges currently limit the depth of research insight provided by the available data. In this Perspective, we review clinical reports describing the use of circulating tumour DNA to detect mechanisms of acquired resistance to targeted therapies, predominantly in patients with advanced-stage non-small-cell lung cancer, and highlight key unresolved questions with the aim of moving towards more-informative research studies.
- 31 May 2024
- Published by Elsevier in Lung Cancer
- Vol. 193, 107844
Exploring the use of circulating tumor DNA for mutational signature analysis
- 31 May 2024
- Published by Elsevier in Lung Cancer
- Vol. 193, 107844
Exploring the use of circulating tumor DNA for mutational signature analysis
- Open Access
- 12 April 2024
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 19 (7) , 995-1006
Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib
- 12 April 2024
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 19 (7) , 995-1006
Open AccessClinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib
- Open Access
- 19 March 2024
- Published by Elsevier in EBioMedicine
- Vol. 102, 105074
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis
- 19 March 2024
- Published by Elsevier in EBioMedicine
- Vol. 102, 105074
Open AccessHepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis
- 1 September 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 7 (7) , e2300451
Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases
Two cases show osimertinib/sotorasib combination could be effective in KRAS G12C-driven osimertinib resistance.
- 1 September 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 7 (7) , e2300451
Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases
Two cases show osimertinib/sotorasib combination could be effective in KRAS G12C-driven osimertinib resistance.
- Open Access
- 16 May 2023
- Published by Elsevier in Lung Cancer
- Vol. 181, 107248
Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI’s: Exploration of efficacy of unselected treatment in a multicenter cohort study
- 16 May 2023
- Published by Elsevier in Lung Cancer
- Vol. 181, 107248
Open AccessChemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI’s: Exploration of efficacy of unselected treatment in a multicenter cohort study
- Open Access
- 19 December 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 181, 53-61
Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy
- 19 December 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 181, 53-61
Open AccessPrevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy